TMDX Q3 2022 Earnings — TransMedics Group, Inc. Revenue & Financial Results | Market Cap Arena

TMDXTransMedics Group, Inc.

$5B

Q3 2022 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$26M+378.3% YoY

Gross Profit

$18M70.5% margin

Operating Income

-$6M-21.6% margin

Net Income

-$7M-28.9% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+25.2%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$17M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$275M

Total Liabilities

$87M

Stockholders' Equity

$188M

Cash & Equivalents

$204M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$5M	+378.3%
Gross Profit	$18M	$4M	+380.1%
Operating Income	-$6M	-$12M	+52.7%
Net Income	-$7M	-$13M	+42.7%

Revenue Segments

Ocs Liver Product

$13M49%

Ocs Heart Product

$12M45%

Ocs Lung Product

$2M6%

Geographic Segments

UNITED STATES

$23M91%

Other Countries

$2M9%